Kayar da Ciwon daji Tare da CAR T Cell Therapy A Indiya
Nemo bege da warkarwa tare da CAR T Cell Therapy a Indiya.
Tuntuɓi, kuma za mu haɗa ku tare da manyan asibitoci a Indiya don maganin CAR T-Cell.
Kamfanoni kamar Immunoact, Cellogen da Immuneel suna yin CAR T tantanin halitta a Indiya. Indiya ta mai da hankali sosai ga maganin CAR T-cell, wanda shine sabon nau'in rigakafi. A cikin wannan sabon magani, ana sake tsara ƙwayoyin garkuwar marasa lafiya don ganowa da kashe ƙwayoyin cutar kansa. A cikin 'yan shekarun da suka gabata, asibitocin Indiya da cibiyoyin nazarin sun yi nisa ga yin amfani da maganin CAR T-cell. CAR T-cell far na iya canza yadda ake bi da ciwon daji, don haka yana ba marasa lafiya waɗanda ba su da sauran zaɓin sabon bege. Akwai shirye-shiryen ƙirƙira da yin CAR T-cell far a Indiya, wanda zai sauƙaƙa samun su da rahusa.
CAR T-Cell Far A Indiya - Matsayin Yanzu
Fabrairu, 2024: A cikin Oktoba 2023, Central Drugs Standard Control Organisation CDSCO), wanda ke daidai da Hukumar Abinci da Magunguna ta Amurka, ta ba da izini ga NexCAR19, wanda ya mai da ita farkon maganin tantanin halitta na CAR-T da aka ba da lasisi a Indiya. CAR T Cell far in India An kaddamar da shi a hukumance a asibitoci 6 a fadin Delhi, Mumbai da Pune.
An ba da lasisin bisa ga binciken daga ƙayyadaddun gwaje-gwaje na asibiti guda biyu da aka gudanar a Indiya da suka ƙunshi jimillar mutane 64 da aka gano suna da cutar sankarar lymphoma ko cutar sankarar bargo. Dangane da sakamakon gwajin da aka bayar a taron Ƙungiyar Ciwon Jiki na Amurka a watan Disamba 2023, an ga cewa kashi 67% na marasa lafiya (36 daga cikin 53) da ke shiga cikin binciken biyu sun sami raguwa mai yawa a cikin girman cutar kansa (maganganun martani). ). Kusan rabin waɗannan marasa lafiya sun sami cikakkiyar bacewar rashin lafiyar (cikakkiyar amsa).
ImmunoACT, wani reshe na IIT Bombay, ya ba da kuɗi don gwajin kuma zai kasance da alhakin samarwa da kasuwancin actalycabtagene autoleucel.
Wasu cibiyoyin ciwon daji a Indiya sun fara CAR T-Cell therapy don DLBCL, BALL, Multiple Myeloma, Gliomas, hanta, pancreatic, colon, huhu, mahaifa da ciwon daji na tushen GI tare da taimakon wani kamfani na Malaysia, baya ga gwajin gwaji na asibiti a halin yanzu. ACTREC da Narayana, Bengaluru. Waɗannan cibiyoyin suna ba da jiko na CAR T-Cells tare da haɗin gwiwar Cibiyar Albarkatun Halittar Malesiya. MGRC ta hada kai da wani kamfanin fasahar kere-kere na CAR Cell na kasar Sin don kawowa CAR T-Cell far a Indiya. A cikin wannan jiyya, ana fitar da fararen jinin marasa lafiya, sa'an nan kuma ana tura mai karɓar mai karɓa na chimeric (CAR) zuwa T-Cells. Don wannan tsari, ana jigilar sel marasa lafiya zuwa cibiyar fasahar kere kere a Malaysia. Wadannan Kwayoyin CAR-T ana saka su a baya a cikin majiyyaci. Waɗannan ƙwayoyin da aka sarrafa suna ɗaure da ƙwayoyin kansa kuma suna kashe su.
Maganin CAR T-Cell na gida yana haɓaka cikin sauri sosai a Indiya. Bayan amincewa an yi imani da cewa CAR T-Cell far a Indiya zai kai kusan $ 20,000 USD. Asibitoci a Indiya, wato Tata Memorial, Narayana, Bengaluru, & CMC, Vellore, sun riga sun fara gwaji. Wannan zai ceci rayukan daruruwan marasa lafiya da ke fama da wani nau'in ciwon daji na jini. A halin yanzu, ana samun wannan maganin ceton rai a cikin Amurka, UK, Kanada, Isra'ila, Singapore, China, Malaysia, da Ostiraliya. Nan ba da jimawa ba, zai kasance a Indiya, Koriya ta Kudu, da Japan kuma. Kudin wannan maganin yana kusa 5-7,00,000 USD a Amurka, yayin da a China farashin ko'ina tsakanin $70,000 da $80,000 USD.
Gwajin asibiti don CAR T- Maganin ƙwayar cuta don maganin wasu nau'in ciwon daji na jini ya fara a Cibiyar Kula da Lafiya, Bincike da Ilimin Ciwon daji reshen bincike da ci gaba na Cibiyar Tunawa da Tata. "Za a bayyana ƙarin cikakkun bayanai game da shari'ar nan ba da jimawa ba," in ji Dokta Narula a cikin wani taron manema labarai. Wannan gwaji na asibiti yana faruwa ne tare da taimakon mai bincike daga IIT, Bombay wanda ya haɓaka wannan maganin ceton rai.
Dr Reddys Lab ya kuma kulla yarjejeniya da Shenzen Biopharma Pregene na kasar Sin a cikin watan Mayu, 21 don kawo wannan maganin ceton rai zuwa Indiya. Akwai wasu kamfanoni da dama da su ma suke aikin kawo wannan fasaha zuwa Indiya. Wani Ba’indiye da ke zaune a Amurka Masanin ilimin cututtukan daji Dr. Siddharth Mukherjee ya kasance a Indiya kwanan nan kuma ya sami ganawa da Kiran Mazumdar Shaw na Biocon & Mr. Kush Parmar na 5 AM ventures. Dukkaninsu sun amince da samar da wata hanyar da za ta samar da kwayar cutar ta Chimeric Antigen Receptor (CAR) don yakar cutar kansa. Kamar yadda rahotanni suka nuna, ana iya samun wannan maganin a Indiya cikin kusan shekara guda. An amince da wannan maganin kwanan nan FDA (Gudanar da Abinci da Magunguna). Wannan maganin tantanin halitta yana da amfani don magani a wasu yara da matasa masu fama da cutar lymphoma Non-Hodgkin. Jiyya tare da Yeskarta & Kymriah shine na farko CAR T-Cell far don karɓar FDA amincewa.
Duk da cewa akwai gwaje-gwajen maganin kwayar halitta da yawa da ke aiki da rajista a Amurka, Tarayyar Turai, da China, babu wanda aka samu a Indiya.
Sabuwar cibiyar Immuneel a cikin Birnin Kiwan lafiya na Narayana na Bengaluru an sadaukar da ita don gabatar da ingantattun hanyoyin kwantar da tarzoma masu araha ga Indiya. Wurin dabarar wurin a cikin babban asibitin kulawa kusa da sashin dashen kasusuwa mai girma yana ba da damar ci gaba da daidaitawa tsakanin ƙungiyoyin bincike da likitocin, wanda ke da mahimmanci don haɓaka haɓakar asibiti na sabbin hanyoyin kwantar da hankali kamar CAR-T.
Immuneel yana aiki tukuru don ciyar da bututunsa gaba. Dabarun kamfanin na ba da lasisin kadari na CAR-T wanda aka riga an gwada shi a asibiti ana sa ran zai haifar da gwajin asibiti na farko na kamfanin a cikin 2021. Dangane da dakin gwaje-gwaje da wuraren samarwa, gami da kayan aiki da kayan aiki, haɗin gwiwar Immuneel yana daga cikin. mafi kyau a duniya. Wannan yana taimaka wa likitoci da masana kimiyya suyi aiki tare ba tare da matsala ba a ciki da kuma tare da cibiyoyin bincike a duk faɗin duniya akan ƙirƙirar samfura da rarrabawa. Don tallafawa wannan manufa, ƙungiyar ta jawo hankalin ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwayoyin cuta, da kuma fitacciyar Hukumar Ba da Shawarwari ta Kimiyya da ta ƙunshi ƙwararrun ƙwararrun ƙwararrun kimiya da fasaha na filin.
Wadannan hanyoyin kwantar da hankula suna da karfi sosai, ana sarrafa su sosai, suna buƙatar kayan masarufi / kayan masarufi masu tsada, kuma suna da wahalar sarrafa kansu. Kayan aiki na adanawa da jigilar ƙwayoyin halittar da aka adana na ci gaba da zama matsalar duniya. Saboda duk waɗannan abubuwan, hanyoyin kwantar da kwayar halitta suna da matukar wahalar samarwa da samarwa, don haka suna da tsada sosai. Magungunan kwantar da hankula suna da wuya a tsara asibiti, kuma dole ne a sanya ido kan marasa lafiya don abubuwan da zasu faru a asibiti nan da nan bayan jiko.
Sakamakon Mataki na II CAR T-Cell Therapy Gwajin gwaji A Indiya
A ASCO, Dec 22 taron, Immuneel, farawa tantanin halitta da kwayar halitta, ya sanar da cewa binciken farko daga gwajin gwaji na farko na Indiya na 2 ya nuna kashi 77% na yawan amsawa a cikin kwanaki 90 a cikin marasa lafiya da ciwon jini kamar cutar sankarar bargo da lymphoma. Immuneel yana haɓaka maganin ƙwayar cuta ta CAR-T Varnimcabtagene.
Sakamakon farko daga gwajin IMAGINE ya dogara ne akan shigar da mutane 10 na farko daga cikin jimlar marasa lafiya 24.
A ranar 28, fiye da 80% na marasa lafiya sun sami cikakkiyar farfadowa na asibiti. A ranar 90, bayanan IMAGINE ya bayyana adadin amsa gabaɗaya na 77%, tare da cikakken martani da aka nuna a cikin 6 cikin 9 masu ƙima.
Ranar 28 na marasa lafiya na lymphoblastic cutar sankarar bargo na B mai tsanani da karatun rana na 90 sun nuna 100% da 83% cikakke gafara, bi da bi, yana nuna amsa mai sauri, mai ƙarfi, da kuma dorewa.
Varnimcabtagene ya ɗauki kwanaki 12 akan matsakaita don samarwa da fitarwa, tare da ƙimar nasarar masana'anta 100%.
Kiran Mazumdar-Shaw, shugabar Biocon, Siddhartha Mukherjee, sanannen masanin ilimin likitanci kuma marubuci, da Kush Parmar, mai kula da abokin tarayya na 5AM Venture, wanda ya kafa Imuneel. Imuneel yana haɓaka bututun kansa na chimeric antigen receptor T-cell (CAR-T) hanyoyin kwantar da hankali da sauran maganin rigakafi na salula don maganin ciwon daji.
Menene Fadin Motar-T Cell Therapy A Indiya?
Gabatarwa: CAR T-cell far sabon nau'in magani ne wanda ke canza yadda ake bi da cutar kansa a duk duniya. A cikin 'yan shekarun da suka gabata, Indiya ta sami ci gaba mai yawa wajen ɗaukar wannan babban magani, yana ba wa marasa lafiya nau'ikan ciwon daji sabbin dalilai na fata. Maganin kwayar cutar CAR-T na iya yin tasiri sosai kan kula da lafiyar Indiya saboda yana iya canza yadda ake bi da cutar kansa.
Fadada Zaɓuɓɓukan Jiyya: Zuwan magungunan CAR-T a Indiya ya ba wa marasa lafiya ƙarin hanyoyin da za a bi da su, musamman ma masu ciwon daji na jini kamar cutar sankarar bargo da lymphoma. Wannan maganin ya ƙunshi fitar da ƙwayoyin T na majiyyaci, canza su ta hanyar kwayoyin halitta ta yadda za su samar da masu karɓan antigen na chimeric (CARs) waɗanda ke kaiwa ga ƙwayoyin cutar kansa, sannan a mayar da su cikin jikin majiyyaci. CAR-T cell far wata hanya ce ta keɓancewa wacce ke sauƙaƙe tsarin rigakafi don ganowa da kashe ƙwayoyin cutar kansa.
Bincike da raya kasa: R&D sun yi nisa. Indiya tana da ƙaƙƙarfan ababen more rayuwa don bincike da haɓakawa, kuma manyan cibiyoyi da asibitoci suna duban yuwuwar maganin CAR-T. Wannan sadaukarwar don yin nazari ya haifar da sababbin abubuwa masu ban sha'awa, irin su ƙirƙirar hanyoyin kwantar da hankali na CAR-T waɗanda suka dace da bambancin jinsi da kabilanci na mutanen Indiya. Irin waɗannan haɓakawa suna taimakawa wajen faɗaɗa isar da maganin da kuma ba da damar yin amfani da shi akan ƙarin nau'ikan ciwon daji.
Ƙarfafawa da samun dama: Ɗaya daga cikin abubuwa mafi kyau game da maganin CAR-T a Indiya shine, idan aka kwatanta da wasu ƙasashen yammacin duniya, yana da araha. Marasa lafiya daga sassa daban-daban na rayuwa sun fi samun damar yin hakan saboda farashin yayi ƙasa kuma akwai zaɓin magani da yawa. Har ila yau, yawancin asibitocin Indiya da cibiyoyin kiwon lafiya sun yi aiki tare da kamfanonin magunguna na kasa da kasa don kawo magungunan CAR-T zuwa Indiya, wanda ya sauƙaƙa wa mutanen da ke buƙatar ta.
Kalubale da abubuwan da za a sa a gaba: Maganin kwayar halitta na CAR-T yana da dama mai yawa, amma kuma yana da wasu matsaloli. Wasu daga cikin matsalolin da ya kamata a magance su sun hada da tsadar magani, wahalar yin maganin, da kuma buƙatar kayan aiki na musamman. Amma gwamnatin Indiya, tare da yin aiki tare da masu ruwa da tsaki na kiwon lafiya, suna aiki tuƙuru don magance waɗannan matsalolin tare da kafa tsarin tsari don amfani da maganin ta hanyar aminci da inganci.
Amfani da CAR-T cell far a Indiya yana girma da sauri, yana ba masu ciwon daji sabon fata da ingantattun hanyoyin magance cutar su. Indiya wuri ne mai kyau don wannan jiyya mai fa'ida saboda ta himmatu don yin karatu, farashin yayi ƙasa, kuma samun dama yana samun kyau. Yayin da tsarin kula da lafiya na Indiya ke ci gaba da canzawa, ƙarin maganin ƙwayoyin cuta na CAR-T na iya canza yadda ake magance cutar kansa, yana sa abubuwa su zama masu kyau ga marasa lafiya da canza rayuwa.
Bayani Akan Yiwuwar CAR T Cell Therapy A Indiya
A cikin 'yan shekarun nan, Indiya ta fito a matsayin tauraro mai jagora na bege ga masu ciwon daji da ke neman ci gaba da jiyya irin su CAR T Jiyya na ƙwayar cuta a Indiya. CAR T Cell Therapy hanya ce ta juyin juya hali don magance ciwon daji. Yana kai hari da kawar da kwayoyin cutar kansa ta hanyar amfani da tsarin garkuwar jiki.
Wannan ya sa ya zama zaɓi mai ban sha'awa ga yawancin masu fama da ciwon daji, saboda yana da ƙananan illa idan aka kwatanta da magungunan gargajiya. Kuna iya samun wannan sabuwar fasahar a cikin fitattun cibiyoyin kiwon lafiya na Indiya da yawa, kamar Tata Memorial Center, Apollo Cancer Hospital, BLK, Artemis, Oncology Asia, American Oncology, da HCG.
Samuwar CAR T Cell Therapy a cikin waɗannan manyan wuraren kiwon lafiya babban mataki ne a yaƙin Indiya da kansa. Nemo manyan asibitoci 5 da aka sani don samar da mafi kyau Maganin mota T a Indiya.
Tata Memorial Cancer Hospital a Mumbai
Daga cikin manyan masu samar da CAR T Jiyya A Indiya, da farko ya zo sunan asibitin Tata Memorial, wanda ke ba da maganin cutar kansa a duniya. A cikin wannan asibiti, ƙungiyar kwararrun likitoci da masu bincike suna aiki tuƙuru don yaƙi da cutar kansa ta hanyar amfani da manyan jiyya. An san asibitin da kyau a cikin kula da ciwon daji kuma yana da kwarewa mai yawa a cikin amfani da CAR T Cell far don taimakawa marasa lafiya su samu lafiya. Mutane suna zuwa nan daga ko'ina saboda sun amince da Tata Memorial don ba su dama mafi kyau don doke ciwon daji. Don haka, idan kai ko wani da kuka sani yana buƙatar ingantaccen kulawar cutar kansa, Asibitin Ciwon daji na Tata Memorial babban zaɓi ne.
Cibiyar Cancer ta Apollo a Chennai
Cibiyar Ciwon daji ta Apollo da ke Chennai sanannen cibiyar kiwon lafiya ce da aka sani da kyakkyawan sabis na kula da cutar kansa. Suna ba da cikakkiyar kulawa ga masu fama da ciwon daji ta hanyar fasaha mai zurfi da kuma ƙwararrun ƙwararrun likitocin oncologists. Tawagarsu ta sadaukar da kai ta likitocin oncologists, likitocin fiɗa, da ma'aikatan tallafi suna aiki tuƙuru don ƙirƙirar tsare-tsaren jiyya na keɓaɓɓen waɗanda ke ba da fifiko ga inganci da ingancin rayuwar mai haƙuri. Yunkurinsu na ƙwazo ya sa sun yi suna a fagen kula da cutar daji.
Cibiyar Ciwon daji ta Kasa (AIIMS) A Delhi
Cibiyar Ciwon daji ta Kasa (AIIMS) a Delhi wata babbar cibiya ce ta hanyoyin kwantar da hankali ta CAR-T. Kuna iya samun damar yin amfani da maganin CAR-T anan akan farashi mafi araha. Wannan cibiya ta likitanci ta shahara saboda ci-gaba da bincike game da maganin ƙwayoyin cuta na immunoadoptive, manyan wurare, da ƙwararrun likitoci. Cibiyar tana ɗaukar tsarin ƙungiya, ta haɗa ƙwararrun likitocin cutar kanjamau, likitocin fiɗa, likitocin rediyo, da ma'aikatan tallafi don ƙirƙirar tsare-tsaren jiyya na keɓaɓɓen cutar kansar jini da sauran nau'ikan ciwon daji. Har ma suna amfani da fasaha na ci gaba kamar hankali na wucin gadi da nazarin kwayoyin halitta don samar da mafi kyawun kulawar ciwon daji ga marasa lafiya.
BLK Max Cibiyar Cancer, Delhi
Cibiyar Ciwon daji ta BLK Max a Delhi tana ɗaya daga cikin manyan asibitocin ciwon daji na Indiya, waɗanda aka keɓe don samar da maganin ƙwayoyin cuta na antigen receptor t cell (CAR T). Cibiyar su tana da fasaha na ci gaba don kula da kansa wanda ya haɗa da aikin tiyata na mutum-mutumi, maganin tomo, da immunotherapy. Yanayin dumi da tallafi na iya taimaka maka ka kasance da karfi da yaki da cutar.
Rajiv Gandhi Cibiyar Cancer & Cibiyar Bincike A Delhi
Cibiyar Cancer ta Rajiv Gandhi & Cibiyar Bincike a Delhi tana ɗaya daga cikin manyan cibiyoyin ciwon daji na Asiya. Ƙwararrun fasahar su da ma'aikata masu basira suna ba da kulawar ciwon daji na duniya ga marasa lafiya a Indiya, da kuma a cikin ƙasashen SAARC. Cibiyar ta sami karramawa na tasiri ga rayuwar kusan 2.75 lakh marasa lafiya tun lokacin da aka kafa a 1996. Kwararrun su yana ba da mafi kyawun kulawa ga masu ciwon daji ta hanyar maganin CAR T Cell mai tsada a Indiya.
Haɗu da Manyan Likitocin Oncologists Don CAR T Cell far A Indiya
Koyi game da manyan oncologists don CAR T Jiyya A Indiya. Waɗannan ƙwararrun likitocin sun himmatu wajen samar da mafi kyawun maganin tantanin halitta don ciwon daji tare da keɓaɓɓen kulawa da tallafi. Amince da gwanintarsu don samun kyakkyawar makoma a yaƙin ku da kansa!
Dr T Raja (MD, DM)
Dokta T Raja sanannen Likitan Oncologist ne tare da gogewa sama da shekaru 25 akan maganin cutar kansa. Ya shahara da fitaccen iliminsa kuma ana masa kallon daya daga cikin manyan likitocin Indiya. Dr. Raja kuma yana da babban matsayi na ilimi, yana jagorantar shirin DNB Medical Oncology a Asibitin Musamman na Apollo a Chennai. Shi mai magana ne da ake nema a tarukan kasa da kasa, inda yake ba da bayanai masu ma'ana.
Dr Srikanth M (MD, DM)
Dr. Srikanth M. kwararre ne a fannin ilmin jini a Chennai, wanda aka sani da gwanintarsa wajen magance cututtuka daban-daban da suka shafi jini. Ya ƙware a cikin batutuwan lafiya na ɗan gajeren lokaci da na dogon lokaci kamar anemia, myeloma, lymphomas b-cell da cutar sankarar bargo. Dr. Srikanth M. kuma yana ba da gwaje-gwaje na ci gaba don duba lafiyar ku gabaɗaya, kamar buri na kasusuwa da maganin chelation don lokuta da ba kasafai ba kamar yawan ma'adanai a cikin jini. Dr. Srikanth M. ya sami lambobin yabo don gudunmawar da ya bayar ga bincike na myeloma, wanda ya sa ya zama ƙwararren ƙwararren likita a cikin ilimin jini wanda ke shirye ya ba da kulawa ta musamman ga marasa lafiya da suke bukata.
Dr Revathi Raj (MD, DCH)
Dokta Revathi Raj kwararriya ce da ake mutuntawa sosai da aka santa da gwaninta wajen dashen kasusuwa na yara. Ta yi nasarar gudanar da fiye da 2000 daga cikin wadannan dashen, wanda ya zama babbar kwararre a Indiya. Dokta Raj yana da kwarewa mai yawa wajen kula da yara masu ciwon jini irin su thalassaemia, hemophilia, sickle cell anemia, aplastic anemia, da cutar sankarar bargo. Ta himmatu sosai ga jin daɗin yara, tana gudanar da sabis na musamman don cutar sankarar yara da lymphoma tare da adadin magani na 80%.
Farashin Motar T-Cell Therapy A Indiya
A ranar 13 ga Oktoba, 2023, wani kamfani mai suna Immunoadoptive Cell Therapy Private Limited (ImmunoACT) a Mumbai ya sami izini daga Central Drug Standard Control Organisation (CDSCO) don maganin kansa na farko na Indiya mai suna NexCAR19.
An tsara wannan magani na musamman don taimaka wa mutanen da ke da wasu nau'in cutar sankarar bargo da lymphoma waɗanda ba su amsa wasu jiyya ba. An gudanar da gwajin gwaji na wannan tsari a kan marasa lafiya 60 da lymphomas da leukemia. Yawan amsa gabaɗayan wannan gwaji na asibiti shine kashi 70% wanda ya nuna shi azaman ingantaccen magani don lalata ƙwayoyin cutar kansa sosai.
The Farashin CAR T cell far a Indiya kusan USD 57,000. Wannan farashin ya yi ƙasa sosai idan aka kwatanta da ƙasashe kamar China. Koyaya, yana da mahimmanci a lura cewa wannan farashin na iya bambanta dangane da dalilai iri-iri. Kudin jiyya na CAR-T na iya bambanta daga wannan asibiti zuwa wancan ya danganta da fasaharsu, ƙwarewarsu, da sauran wurare.
Bugu da ƙari kuma, nau'in maganin CAR T-cell da ake buƙata da yanayin majiyyaci na iya shafar ƙimar gabaɗaya. Kasuwancin Indiya kamar Immunoact, Immuneel, da Cellogen nan ba da jimawa ba za su ƙaddamar da nasu jiyya na CAR T-Cell, wanda zai kai tsakanin $30,000 zuwa $40,000. Sakamakon haka, Indiya za ta kasance cikin mafi kyawun wurare masu tsada don maganin CAR T-cell.
Menene Maganin T-Cell Mota?
Chimeric antigen receptor T-cell far, wanda aka fi sani da CAR T-cell therapy, wani maganin rigakafi ne mai rushe ƙasa wanda ya canza gaba ɗaya yadda ake bi da ciwon daji. Yana ba wa marasa lafiya da wasu cututtukan daji fata waɗanda aka gani a baya a matsayin ba za a iya warkewa ba ko kuma suna da ƴan hanyoyin warkewa.
Maganin ya haɗa da yin amfani da ƙwayoyin rigakafi na majiyyaci-musamman, ƙwayoyin T-da kuma gyara su don inganta ƙarfin su don ganowa da lalata ƙwayoyin cutar kansa. Don yin wannan, ana ba da ƙwayoyin T na ƙwayoyin cuta na chimeric antigen receptor (CAR), wanda ke ba su ikon kai hari kan wasu sunadaran sunadaran, ko antigens, a saman ƙwayoyin cutar kansa.
An fara cire ƙwayoyin T daga majiyyaci, sannan a canza su ta hanyar kwayoyin halitta don bayyana CAR. A cikin dakin gwaje-gwaje, waɗannan sel da aka canza suna haɓaka don samar da adadi mai yawa na ƙwayoyin CAR T, sannan a mayar da su cikin jinin mara lafiya.
Da zarar sun shiga cikin jiki, ƙwayoyin CAR T suna samun ƙwayoyin kansa waɗanda ke bayyana antigen da ake so, suna manne musu, kuma suna haifar da amsawar rigakafi. Kwayoyin CAR T da aka kunna suna yaduwa kuma suna kai hari kan ƙwayoyin cutar kansa, suna kashe su.
Lokacin da aka yi amfani da shi don magance wasu cututtuka na jini kamar m lymphoblastic cutar sankarar bargo (ALL) da takamaiman nau'i na lymphoma, CAR T-cell far ya nuna sakamako na musamman. Ya haifar da ƙima mai ƙima da kuma a wasu marasa lafiya, har ma da dawwamammen gafara.
CAR T-cell far, duk da haka, hanya ce mai ƙwarewa kuma ta musamman wacce za ta iya samun haɗari da illa. Cytokine saki ciwo (CRS), wani tartsatsi na rigakafi dauki wanda zai iya haifar da mura-kamar bayyanar cututtuka da kuma, a cikin matsananci yanayi, gabobin jiki gazawar, na iya dandana daga wasu mutane. Haka kuma an sami rahotanni game da illar cutar jijiya, duk da haka ana iya warkewa akai-akai.
Duk da waɗannan matsalolin, CAR T-cell far wani gagarumin ci gaba ne a cikin yaƙi da ciwon daji kuma yana nuna babban damar nan gaba. Binciken na yanzu yana mai da hankali kan haɓaka ingancinsa da bayanin martabarsa tare da faɗaɗa amfaninsa zuwa nau'ikan ciwon daji daban-daban. CAR T-cell far yana da ikon canza fuskar maganin ciwon daji da ba marasa lafiya a ko'ina sabon bege tare da ci gaba.
hanya
Tsarin jiyya na CAR-T, wanda ke ɗaukar makonni kaɗan, ya ƙunshi matakai da yawa:
Ana fitar da ƙwayoyin T daga jinin ku ta amfani da bututu da aka sanya cikin jijiya ta hannu. Wannan yana ɗaukar sa'o'i biyu.
Kwayoyin T ana jigilar su zuwa wani wuri inda suke yin gyare-gyaren kwayoyin halitta don zama ƙwayoyin CAR-T. Makonni biyu zuwa uku sun wuce duk wannan.
Ana sake dawo da ƙwayoyin CAR-T cikin jinin ku ta ɗigo. Wannan yana buƙatar sa'o'i da yawa.
Kwayoyin CAR-T sun yi niyya kuma suna kawar da kwayoyin cutar kansa a cikin jiki. Bayan karbar maganin CAR-T, za a sa ido sosai.
Wani nau'in Kwayoyin Ciwon daji Za a iya Magance su da Motar-T Cell Therapy?
Sai kawai marasa lafiya da balagaggu B-cell wanda ba lymphoma Hodgkin ko yara masu fama da cutar sankarar lymphoblastic na yara waɗanda suka riga sun gwada jiyya na al'ada guda biyu waɗanda ba su yi nasara ba a halin yanzu suna iya amfani da samfuran CAR T-cell waɗanda suka sami amincewar FDA. Koyaya, yanzu ana gwada maganin CAR T-cell a cikin karatun asibiti azaman jiyya na layi na farko ko na biyu don ƙwayar lymphoma balagaggu da cutar sankarar yara mai tsanani na lymphoblastic na yara. Kwanan nan, wasu daga cikin binciken sun nuna nasarori masu ban mamaki a lokuta masu ƙarfi kamar glioblastoma, gliomas, ciwon hanta, ciwon huhu, ciwon GI, ciwon daji na pancreatic da kuma ciwon daji na baki.
Don ƙare
Wannan yana wakiltar ci gaba mai mahimmanci a cikin kula da cutar sankarar bargo da B-cell lymphoma. Bugu da ƙari, yana ba da bege ga waɗanda aka yi hasashen rayuwarsu za ta wuce watanni shida kacal. Yanzu da muka gano hanyoyin juriya kuma mun ƙirƙiri ƙarin dabaru don yaƙar su, nan gaba yana da alama ya fi dacewa.
Tuntuɓi ƙwararrun ƙwararrun masu ba da lafiya a nan a Faxar Cancer don shawarwari na kyauta don tsara tsarin kulawa mai dacewa don bukatun ku na kiwon lafiya. Da fatan za a aika da rahoton likitan ku zuwa info@cancerfax.com ko WhatsApp zuwa + 1 213 789 56 55.
Menene Fa'idodin Car-T Cell Therapy?
Babban fa'idar ita ce maganin CAR T-cell yana buƙatar jiko ɗaya kawai kuma galibi yana buƙatar makonni biyu na kulawar marasa lafiya. Marasa lafiya da lymphoma ba Hodgkin da cutar sankarar yara da aka gano kwanan nan, a gefe guda, yawanci suna buƙatar chemotherapy na akalla watanni shida ko fiye.
Amfanin maganin CAR T-cell, wanda shine ainihin magani mai rai, na iya dawwama shekaru da yawa. Idan kuma lokacin da sake dawowa ya faru, ƙwayoyin za su iya ganowa da kuma kai hari ga ƙwayoyin cutar kansa saboda suna iya rayuwa a cikin jiki na tsawon lokaci.
Kodayake bayanin yana ci gaba, kashi 42 cikin 19 na marasa lafiya na lymphoma manya waɗanda suka yi amfani da CD15 CAR T-cell magani har yanzu suna cikin gafara bayan watanni XNUMX. Kuma bayan watanni shida, kashi biyu bisa uku na marasa lafiya da ke fama da cutar sankarar mahaifa mai tsanani na lymphoblastic na yara har yanzu suna cikin gafara. Abin takaici, waɗannan majiyyatan suna da ciwace-ciwacen ciwace-ciwacen daji waɗanda ba a samu nasarar yi musu magani ta amfani da ƙa'idodin kulawa na gargajiya ba.
Wane nau'in marasa lafiya ne za su zama masu karɓa na CAR-T Cell Therapy?
An gwada marasa lafiya tsakanin shekaru 3 zuwa shekaru 70 tare da maganin CAR T-Cell don nau'in ciwon daji na jini daban-daban kuma an gano yana da tasiri sosai. Cibiyoyi da yawa sun yi iƙirarin ƙimar nasara fiye da 80%. Mafi kyawun ɗan takarar don CAR T-cell far a wannan lokacin shine ƙaramin yaro tare da cutar sankarar lymphoblastic mai tsanani ko kuma balagagge tare da lymphoma mai tsanani na B-cell wanda ya riga ya sami layi biyu na rashin tasiri.
Kafin ƙarshen 2017, babu wani tsarin kulawa da aka yarda da shi ga marasa lafiya waɗanda suka riga sun shiga cikin layi biyu na jiyya ba tare da samun gafara ba. Magani kawai da FDA ta amince da shi wanda ya zuwa yanzu ya tabbatar da cewa yana da fa'ida sosai ga waɗannan marasa lafiya shine CAR T-cell far.
Yaya Tasirin Motar-T Cell Far?
CAR T-cell far ya kasance mai tasiri sosai wajen magance wasu nau'in ciwon daji na jini, kamar cutar sankarar bargo na lymphoblastic (ALL) da lymphoma ba Hodgkin. A cikin gwaje-gwaje na asibiti, ƙimar amsawar sun kasance da kyau sosai, kuma yawancin marasa lafiya sun shiga cikin cikakkiyar gafara. A wasu lokuta, mutanen da suka gwada kowane magani sun sami gafara na dindindin ko ma yiwuwar warkewa.
Ɗaya daga cikin mafi kyawun abubuwa game da maganin CAR T-cell shine cewa yana kai hari ga ƙwayoyin da suka dace. Masu karɓar CAR waɗanda aka ƙara zuwa ƙwayoyin T suna iya samun takamaiman alamomi akan ƙwayoyin cutar kansa. Wannan yana ba da damar ba da magani da aka yi niyya. Wannan hanyar da aka yi niyya tana cutar da ƙwayoyin lafiya kaɗan gwargwadon yuwuwa kuma tana rage haɗarin illolin da ke zuwa tare da jiyya na gargajiya kamar chemotherapy.
Amma yana da mahimmanci a tuna cewa CAR T-cell far har yanzu wani sabon yanki ne wanda har yanzu yana canzawa. Masu bincike da likitoci suna aiki tuƙuru don magance matsaloli kamar tsadar tsada, yuwuwar sakamako mai tsanani, da gaskiyar cewa yana aiki ne kawai ga wasu nau'ikan cutar kansa.
A ƙarshe, maganin CAR T-cell ya nuna hanya ce mai nasara sosai don magance wasu nau'in ciwon daji na jini. Ko da yake hanya ce mai ban sha'awa da ƙarfi, ana buƙatar ƙarin nazari da gwaje-gwaje na asibiti don inganta shi da nemo sababbin hanyoyin amfani da shi. CAR T-cell far na iya canza yadda ake bi da kansa kuma ya sa abubuwa su zama mafi kyau ga mutane a duk faɗin duniya idan ta ci gaba da samun gyaruwa.
Haɗa & Ma'auni
Ma'auni na Haɗa don CAR T-Cell Far:
1. Marasa lafiya tare da CD19+ B-cell Lymphoma (Aƙalla 2 kafin hadewar chemotherapy)
2. Yayi shekaru 3 zuwa 75
3. ECOG ci ≤2
4. Matan da zasu iya haihuwa dole ne suyi fitsari ciki gwajin da aka tabbatar kuma an tabbatar dashi mara kyau kafin maganin. Duk marasa lafiya sun yarda suyi amfani da ingantattun hanyoyin hana daukar ciki a lokacin gwajin har zuwa lokacin binsu na karshe.
Sharuɗɗan Keɓe Don CAR T-Cell Far:
1. Hawan jini a cikin kwakwalwa ko suma
2. Rashin numfashi
3. Yada yaduwar jijiyoyin cikin jini
4. Hematosepsis ko Ciwo mai aiki mara ƙarfi
5. Rashin sarrafawa ciwon sukari
Menene Illolin Car-T Cell Therapy?
A ƙasa an ambata wasu daga cikin illolin maganin CAR T-Cell.
- Ciwon saki na cytokine (CRS): Mafi rinjaye kuma mai yuwuwa gagarumin tasirin maganin CAR T-cell shine ciwon saki na cytokine (CRS). Alamu masu kama da mura, gami da zazzabi, gajiya, ciwon kai, da ciwon tsoka, ana kawo su ta hanyar gyare-gyaren ƙwayoyin T na cytokines. A cikin matsanancin yanayi, CRS na iya haifar da matsanancin zafin jiki, hauhawar jini, gazawar gabobin jiki, har ma da sakamako mai illa.
- Gubar Neurological: Wasu marasa lafiya na iya haifar da sakamako masu illa na jijiyoyi, wanda zai iya bambanta da tsanani daga ƙananan alamu kamar ruɗani mai sauƙi da rashin fahimta zuwa mafi tsanani kamar seizures, delirium, da encephalopathy. Bayan jiko na T-cell na CAR, yawan guba na jijiyoyin jiki yana faruwa akai-akai a cikin makon farko.
- Cytopenia: Maganin CAR T-cell zai iya haifar da ƙananan ƙwayoyin jini, irin su anemia (ƙananan ƙwayar jinin jini), neutropenia (ƙananan ƙwayar jinin jini), da kuma thrombocytopenia (ƙananan adadin platelet). Cututtuka, zub da jini, da gajiyawa suna cikin haɗarin da waɗannan cytopenia za su iya tsananta.
- Cututtuka: CAR T-cell therapy's ƙwanƙwasa ƙwayoyin rigakafi masu lafiya yana ƙara haɗarin ƙwayoyin cuta, ƙwayoyin cuta, da fungal. Domin hana kamuwa da cututtuka, ana iya buƙatar majiyyata a sa ido sosai kuma a ba su magunguna na rigakafi.
- Tumor Lysis Syndrome (TLS): Bayan CAR T-cell far, yana yiwuwa a wasu yanayi a iya sakin adadin abubuwan da ke cikin tantanin halitta zuwa cikin jini saboda saurin kashe ƙwayoyin tumor. Wannan na iya haifar da rashin daidaituwa na rayuwa, kamar yawan potassium, uric acid, da matakan phosphate, wanda zai iya lalata kodan kuma ya haifar da wasu matsaloli.
- Hypogammaglobulinemia: Maganin CAR T-cell yana da yuwuwar rage ƙwayar ƙwayar cuta, wanda zai iya haifar da hypogammaglobulinemia. Wannan na iya sa kamuwa da cuta mai maimaitawa ya fi yuwuwa kuma yana kira don ci gaba da maye gurbin maganin rigakafi.
- Yawan Guba: CAR T-cell far yana da yuwuwar cutar da gabobin da dama, gami da zuciya, huhu, hanta, da koda. Wannan na iya haifar da gwaje-gwajen aikin koda mara kyau, al'amuran numfashi, matsalolin zuciya, da gwajin aikin hanta mara kyau.
- Hemophagocytic lymphohistiocytosis (HLH): Cutar da ba kasafai ba amma mai yiwuwa mai saurin kisa da ake kira hemophagocytic lymphohistiocytosis (HLH) na iya tasowa a sakamakon maganin CAR T-cell. Ya haɗa da wuce gona da iri na ƙwayoyin rigakafi, wanda ke haifar da mummunar lalacewar gabobin da kumburi.
- Hypotension da Riƙewar Ruwa: Sakamakon cytokines da ƙwayoyin CAR T suka saki, wasu marasa lafiya na iya haifar da ƙananan hawan jini (hypotension) da riƙewar ruwa. Don magance waɗannan alamomin, ana iya buƙatar matakan tallafi gami da ruwan jijiya da magunguna.
- Malignancin Sakandare: Rahotanni na malignancies na biyu da ke fitowa bayan maganin CAR T-cell sun wanzu, duk da ƙarancinsu. A halin yanzu ana gudanar da bincike kan yuwuwar kamuwa da cutar ta biyu da kuma haɗari na dogon lokaci.
Yana da kyau a tuna cewa ba kowane majiyyaci ne zai sami waɗannan illolin ba, kuma matakin hankalin kowane mutum zai bambanta. Don ragewa da rage girman waɗannan abubuwan da zasu iya haifar da illa, ƙungiyar likitocin suna bincikar marasa lafiya sosai kafin, lokacin, da kuma bayan maganin CAR T-cell.
Lokaci
Bincika ƙasa jimlar firam ɗin lokacin da ake buƙata don kammala aikin CAR T-Cell. Kodayake tsarin lokaci ya dogara da yawa akan nisan lab daga asibitin da ya shirya na CAR.
- Jarabawa & gwaji: mako guda
- Pre-treatment & T-Cell Tarin: mako guda
- Shirye-shiryen T-Cell & dawowa: makonni biyu zuwa uku
- 1st Tasirin bincike: makonni uku
- 2nd Tasirin Bincike: makonni uku.
Jimlar lokacin: 10-12 Makonni
Ta Yaya Zamu Iya Taimaka muku Samun Mafi kyawun Maganin Ciwon daji a Indiya?
Nemo mafi kyawun maganin ciwon daji a Indiya na iya zama da wahala sosai, musamman idan kun damu da kashe kuɗi da inganci. A nan ne CancerFax zai iya jagorantar ku kamar aboki na gaskiya!
Muna sane da cewa lafiyar ku na da matuƙar mahimmanci kuma yin sulhu akan ingancin kulawa ba zaɓi bane. Shi ya sa muka zabo kwararrun likitoci a hankali kuma muka yi hadin gwiwa da asibitoci da yawa a wurare daban-daban na farashi don ku sami mafi dacewa da bukatun ku. Ta wannan hanyar, zaku iya samun kyakkyawar kulawa ba tare da karya banki ba. A cikin shekaru 10 da suka gabata, tsarinmu ya riga ya taimaki marasa lafiya daga manyan ƙasashe sama da 8, kuma mun himmatu don yin haka a gare ku. Amince da mu don karɓar mafi kyawun CAR T Cell far a Indiya.
Hanya Mafi Sauƙaƙa Na Samun CAR T Cell Therapy A Indiya
Aika Rahotonku
Raba tarihin likitan ku, gami da rahotannin jini na kwanan nan, sakamakon biopsy, da binciken PET, tare da mu a info@cancerfax.com. Wannan muhimmin mataki yana ba mu damar tantance yanayin ku kuma mu jagorance ku zuwa ga mafi dacewa magani.
Kima & Ra'ayi
Ƙwararrun ƙwararrun mu za su yi bitar rahotannin ku a hankali don samar da cikakkiyar ƙima da ra'ayin ƙwararru. Wannan yana taimaka mana sanin mafi kyawun tsarin aiki da ba da shawarar asibitoci mafi dacewa da ƙwararrun likitocin CAR T Cell therapy kamar yadda ya dace da kasafin ku.
Visa da Tafiya
Za mu taimake ku wajen samun takardar izinin likita kuma za mu tsara tsarin tafiyarku. Manufar mu ita ce a sauƙaƙe tafiyarku don ku iya mai da hankali kan jiyya da murmurewa.
Magani Da Bibiya
Da zarar kun isa asibitin da kuka zaɓa, ƙungiyarmu masu sadaukarwa za su ci gaba da taimaka muku a duk lokacin aikin jiyya. Muna haɓaka sadarwa mara kyau tsakanin ku da ma'aikatan lafiya, tare da tabbatar da samun mafi kyawun magani. Zaman lafiyar ku ya kasance babban fifikonmu.
FAQs Akan Maganin T-Cell Mota A Indiya
Menene CAR T-cell far?
- CAR T-cell far wani nau'i ne na immunotherapy wanda ya haɗa da canza ƙwayoyin T na majiyyaci don ganewa da kai hari kan ƙwayoyin cutar kansa. Wannan magani na musamman ya nuna sakamako mai ban sha'awa a cikin wasu nau'in ciwon daji.
Ana samun maganin CAR T-cell a Indiya?
- Ee, ana samun maganin CAR T-cell a Indiya a wasu cibiyoyin ciwon daji na musamman. Koyaya, samuwarta na iya bambanta, kuma ana iya iyakance shi ga wasu nau'ikan cututtukan daji.
Wadanne cututtuka ne za a iya bi da su tare da CAR T-cell far a Indiya?
- Tun daga sabuntawata ta ƙarshe, an yi amfani da maganin CAR T-cell da farko don magance wasu nau'ikan cututtukan daji na jini, kamar cutar sankarar bargo da lymphoma. Takamaiman cutar kansar da suka cancanci magani na iya dogara da ƙa'idodin da cibiyoyin kiwon lafiya ɗaya ke bi.
Menene farashin CAR T-cell far a Indiya?
- Farashin CAR T-cell far na iya zama babba. Yana iya haɗawa da kuɗin tattarawa da gyaggyarawa ƙwayoyin T na majiyyaci, hanyoyin gwaje-gwaje, da gudanar da maganin. Kudin na iya bambanta dangane da nau'in ciwon daji da ake kula da shi da kuma wurin kiwon lafiya.
Shin akwai wasu illolin maganin CAR T-cell?
- Ee, kamar kowane magani na likita, CAR T-cell far na iya samun illa. Abubuwan illa na yau da kullun sun haɗa da ciwo na sakin cytokine (CRS) da kuma cututtukan neurologic. Mummunan illolin na iya bambanta tsakanin daidaikun mutane.
Yaya nasarar maganin CAR T-cell wajen magance cutar kansa?
- CAR T-cell far ya nuna gagarumar nasara wajen magance wasu nau'in ciwon daji, musamman ciwon daji na jini. Duk da haka, tasirinsa na iya bambanta dangane da nau'i da mataki na ciwon daji, da kuma abubuwan da ke cikin marasa lafiya.
Shin CAR T-cell far yana rufe da inshora a Indiya?
- Rufe ta inshora na iya bambanta. Yana da mahimmanci a bincika mai bada inshora da wurin kiwon lafiya da ke ba da magani don fahimtar zaɓuɓɓukan ɗaukar hoto.
Ta yaya zan iya samun damar maganin CAR T-cell a Indiya?
- Marasa lafiya masu sha'awar maganin CAR T-cell ya kamata su tuntuɓi masana oncologists da ma'aikatan kiwon lafiya waɗanda suka kware a wannan jiyya. Za su iya jagorantar marasa lafiya ta hanyar kimantawa da ƙayyade cancanta.